The Causal Association between Total Bilirubin, Direct Bilirubin, and Ulcerative Colitis: A Two-Sample Mendelian Randomization Study.

Bilirubin, a product of heme metabolism, has been linked to various inflammatory conditions. Ulcerative colitis, a chronic inflammatory bowel disease, and the causal relationship between bilirubin and ulcerative colitis remains unclear. This study investigates whether bilirubin levels have a causal effect on the risk of ulcerative colitis using a Mendelian randomization approach. We used the data of total bilirubin, direct bilirubin, and ulcerative colitis obtained from genome-wide association studies (GWAS) to evaluate the effects of bilirubin on ulcerative colitis by using a two-sample MR. The inverse variance weighted method was conducted to assess the primary outcomes, and multivariate MR analyses were performed to combine estimates of the causal effects of multiple risk factors. Four additional analyses, namely, MR-Egger regression, weighted median, weighted mode, and MR-Robust Adjusted Profile Score, were used to investigate the causal association and the influence of potential pleiotropy. In the univariate MR analysis, elevated bilirubin level was associated with decreased risk of ulcerative colitis (Odds ratio [OR] = 0.189, 95% confidence interval [CI]: 0.072-0.492). In the reverse MR analysis, no significant causal relationship between UC and bilirubin levels was observed. After adjusting for confounding factors such as smoking, drinking, type 2 diabetes mellitus, and obesity, total bilirubin was also associated with reduced UC risk (OR = 0.181, 95% CI: 0.104-0.315). Additionally, no causal association was found between direct bilirubin and UC (OR = 0.338, 95% CI: 0.022-5.092). The two-sample MR analysis showed a causal relationship between total bilirubin and ulcerative colitis. Further research is warranted to elucidate the underlying mechanisms and to explore the clinical implications of these findings, including the potential for bilirubin-based therapeutic strategies in ulcerative colitis management.